Étude à long terme, en ouvert, de SAR447537 (INBRX-101) chez les adultes atteints d'emphysème dû à un déficit en alpha-1 antitrypsine
Alpha-1 antitrypsin deficiency (AATD) is a rare genetic condition. People with AATD do not produce enough of a protective protein, which can cause lung damage known as emphysema. This makes breathing difficult and can worsen over time. This Phase 2 trial is evaluating an experimental medicine called SAR447537 (also known as INBRX-101). The treatment aims to replace the missing protein to help protect the lungs. In this study, researchers want to see how safe the drug is when taken over a longer period and how well it works. The study is 'open-label', meaning every participant receives the real medicine rather than a dummy drug (placebo). It is open to non-smoking adults aged 18 to 80 who have emphysema caused by AATD. Participants will have regular clinic visits for health checks, blood tests, and breathing tests to monitor their response.
En un coup d'œil
De quoi parle cette étude ?
Alpha-1 antitrypsin deficiency (AATD) is an inherited condition passed down through families. Normally, the liver produces a protein that protects the lungs from irritation and infection. Without enough of this protein, natural enzymes in the body can slowly break down delicate lung tissue. This causes emphysema, a condition where the tiny air sacs in the lungs become damaged, leading to chronic shortness of breath, coughing, and tiredness.
Currently, there are limited treatment options available on the NHS to replace this missing protein. This trial is investigating a new, lab-developed protein therapy called SAR447537 (INBRX-101). It is designed to act like the natural protective protein, staying in the body longer to help shield lung tissue from ongoing damage.
This is a Phase 2 'open-label extension' study. In clinical trials, 'open-label' means that both you and the study doctors know you are receiving the active medicine, so nobody receives an inactive placebo. The term 'extension' means this study follows patients over an extended time to see how well the medicine works in the long run and to check for any unexpected side effects.
Taking part helps researchers discover whether this new medicine could become a safe, regular treatment for people with AATD emphysema in the future, potentially helping people stay active and preserve their lung health.
Points clés
- Tests a new medicine (SAR447537) designed to protect lungs in adults with AATD emphysema.
- Open to non-smoking adults aged 18 to 80 with confirmed AATD and emphysema.
- This is an open-label study, so all participants receive the active medicine rather than a placebo.
- The treatment is given as an intravenous drip during regular hospital visits.
- Participation is entirely voluntary, and you can leave the study at any time.
Qui peut être éligible ?
This study is open to men and women aged between 18 and 80 who have a confirmed diagnosis of alpha-1 antitrypsin deficiency (AATD) and show signs of emphysema caused by the condition. To join, your lung function needs to be at a moderate level (your breathing test score must show at least 30% of what is expected for your age and height), and you must be a non-smoker.
You will not be able to join if you have recently received certain other protein treatments (augmentation therapy) in the last five weeks, or if you have had other biologic treatments in the past 30 days. People who are on an active waiting list for a lung or liver transplant cannot take part.
Additionally, the study is not suitable for people with poorly controlled diabetes, active cancer, severe liver disease, or serious heart problems. If you have recently had a chest infection or a sudden flare-up of your breathing symptoms within the past four weeks, you would need to wait until your health is stable before being considered.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- I am aged between 18 and 80 years old.
- I have been diagnosed with Alpha-1 Antitrypsin Deficiency (AATD) and emphysema.
- I am currently a non-smoker.
- I have not had protein replacement (augmentation) therapy in the past 5 weeks.
- I have not had a chest infection or severe breathing flare-up in the last 4 weeks.
- I am not currently on a waiting list for a lung or liver transplant.
En quoi consiste la participation ?
If you decide to join this study, you will attend an initial screening visit to check your overall health and confirm that the trial is safe for you. This includes breathing tests (spirometry), blood tests, heart checks (ECGs), and physical examinations.
During the study, you will receive SAR447537 as an intravenous infusion (a slow drip into a vein in your arm) at regular hospital visits. The study team will closely monitor you during and after each infusion for any reactions. You will also have scheduled follow-up visits to check your lung function, assess your symptoms, and take routine blood samples. Because this is a long-term study, taking part involves a sustained commitment over several months to years, with regular contact with the specialist research team.
Risques et avantages potentiels
Locations (40)
- UAB Lung Health Center- Site Number : 105Code postal vérifiéBirmingham, États-Unis
- St Joseph's Hospital and Medical Center- Site Number : 126Code postal vérifiéPhoenix, États-Unis
- David Geffen School of Medicine at UCLA- Site Number : 124Code postal vérifiéLos Angeles, États-Unis
- University of California Davis Medical Center- Site Number : 110Code postal vérifiéSacramento, États-Unis
- National Jewish Medical and Research Center- Site Number : 123Code postal vérifiéDenver, United States
- Nuvance Health Medical Practices, Pulmonary & Sleep Specialists- Site Number : 119Code postal vérifiéDanbury, United States
- University of Florida - Gainesville - 1600 SW Archer Rd- Site Number : 101Code postal vérifiéGainesville, États-Unis
- Indiana University- Site Number : 127Code postal vérifiéIndianapolis, États-Unis
- Brigham and Women's Hospital -75 Francis Street- Site Number : 131Code postal vérifiéBoston, États-Unis
- University of Minnesota-420 Delaware Str SE- Site Number : 125Code postal vérifiéMinneapolis, États-Unis
- Hannibal Regional Healthcare System-HRMG-Hannibal- Site Number : 111Code postal vérifiéHannibal, United States
- Columbia University Irving Medical Center- Site Number : 104Code postal vérifiéNew York, États-Unis
Questions fréquentes
What does 'open-label' mean?
It means there is no placebo (dummy medicine) used in this trial. Both you and the study doctors will know that you are receiving the real study treatment.
Do I have to pay to take part?
No. The study medicine and all study-related health tests are provided free of charge. Most trials also reimburse reasonable travel and parking costs.
Ce médicament guérira-t-il ma condition ?
No. AATD is a lifelong genetic condition. The aim of this treatment is to replace missing protein and help slow or prevent further damage to your lungs, rather than cure the root cause.
Can I still see my usual GP and chest doctor?
Yes. The clinical trial team will work alongside your normal healthcare providers and keep them informed about your care throughout the study.
What happens if I change my mind after starting?
You are free to leave the trial at any point. Your decision will not change the standard of medical care you receive from the NHS now or in the future.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.